Bio-Connect
Anti-Cyclin D1 Picoband antibody, PB9370, Western blotting All lanes: Anti Cyclin D1 (PB9370) at 0.5ug/ml Lane 1: Human Placenta Tissue Lysate at 50ug Lane 2: HELA Whole Cell Lysate at 40ug Lane 3: 293T Whole Cell Lysate at 40ug Predicted bind size: 33KD Observed bind size: 33KD
Anti-Cyclin D1 Picoband antibody, PB9370, Western blotting All lanes: Anti Cyclin D1 (PB9370) at 0.5ug/ml Lane 1: Human Placenta Tissue Lysate at 50ug Lane 2: HELA Whole Cell Lysate at 40ug Lane 3: 293T Whole Cell Lysate at 40ug Predicted bind size: 33KD Observed bind size: 33KD
Anti-Cyclin D1 Picoband antibody, PB9370, Western blotting All lanes: Anti Cyclin D1 (PB9370) at 0.5ug/ml Lane 1: Human Placenta Tissue Lysate at 50ug Lane 2: HELA Whole Cell Lysate at 40ug Lane 3: 293T Whole Cell Lysate at 40ug Predicted bind size: 33KD Observed bind size: 33KD

Anti-Cyclin D1 Picoband Antibody

PB9370
Boster Bio
ApplicationsWestern Blot
Product group Antibodies
ReactivityHamster, Human
TargetCCND1
100 ug
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Boster Bio
  • Product Name
    Anti-Cyclin D1 Picoband Antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: The detection limit for Cyclin D1 is approximately 0.1ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.
  • Applications
    Western Blot
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    500 ug/ml
  • Gene ID595
  • Target name
    CCND1
  • Target description
    cyclin D1
  • Target synonyms
    BCL1, D11S287E, PRAD1, U21B31, G1/S-specific cyclin-D1, B-cell CLL/lymphoma 1, B-cell lymphoma 1 protein, BCL-1 oncogene, PRAD1 oncogene
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP24385
  • Protein Name
    G1/S-specific cyclin-D1
  • Scientific Description
    Boster Bio Anti-Cyclin D1/CCND1 Antibody Picoband® catalog # PB9370. Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
  • Reactivity
    Hamster, Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • He Y, Liu HH, Zhou XL, et al. Rutaecarpine Ameliorates Murine N-Methyl-N'-Nitro-N-Nitrosoguanidine-Induced Chronic Atrophic Gastritis by Sonic Hedgehog Pathway. Molecules. 2023,28(17). doi: 10.3390/molecules28176294
    Read this paper
  • Lei S, Du X, Tan K, et al. CRP‑1 promotes the malignant behavior of hepatocellular carcinoma cells via activating epithelial‑mesenchymal transition and Wnt/β‑catenin signaling. Exp Ther Med. 2023,26(1):314. doi: 10.3892/etm.2023.12013
    Read this paper
  • Dong C, Huang S, Sun L, et al. DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression. Sci Rep. 2022,12(1):19775. doi: 10.1038/s41598-022-23837-y
    Read this paper
  • Chen T, Feng G, Xing Z, et al. Circ-EIF3I facilitates proliferation, migration, and invasion of lung cancer via regulating the activity of Wnt/β-catenin pathway through the miR-1253/NOVA2 axis. Thorac Cancer. 2022,13(22):3133-3144. doi: 10.1111/1759-7714.14665
    Read this paper
  • Bai X, Liu X, Li S, et al. Nuciferine Inhibits TMEM16A in Dietary Adjuvant Therapy for Lung Cancer. J Agric Food Chem. 2022,70(12):3687-3696. doi: 10.1021/acs.jafc.1c08375
    Read this paper
  • Zhang X, Chen R, Song LD, et al. SIRT6 Promotes the Progression of Prostate Cancer via Regulating the Wnt/β-Catenin Signaling Pathway. J Oncol. 2022,2022:2174758. doi: 10.1155/2022/2174758
    Read this paper
  • Sun M, Zhou D, Wu J, et al. Sdy-1 Executes Antitumor Activity in HepG2 and HeLa Cancer Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway. Mar Drugs. 2022,20(2). doi: 10.3390/md20020125
    Read this paper
  • Wang X, Xie Z, Lou Z, et al. Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products in vitro. Mol Med Rep. 2021,24(5):pii: 766. doi: 10.3892/mmr.2021.12406.
    Read this paper
  • Lu Z, Song W, Zhang Y, et al. Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer. Front Oncol. 2021,11:648985. doi: 10.3389/fonc.2021.648985
    Read this paper
  • Sanches JGP, Song B, Zhang Q, et al. The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway. Front Oncol. 2021,11:637298. doi: 10.3389/fonc.2021.637298
    Read this paper